| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4859521
Max Phase: Preclinical
Molecular Formula: C34H33F4N5O2
Molecular Weight: 619.66
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CCN1C(=O)[C@@H](NC(=O)c2cccc(C(F)(F)F)c2)[C@@H](c2ccc(F)cc2)c2c(CN3CCCCC3)nn(-c3ccccc3)c21
Standard InChI: InChI=1S/C34H33F4N5O2/c1-2-42-32-29(27(21-41-18-7-4-8-19-41)40-43(32)26-12-5-3-6-13-26)28(22-14-16-25(35)17-15-22)30(33(42)45)39-31(44)23-10-9-11-24(20-23)34(36,37)38/h3,5-6,9-17,20,28,30H,2,4,7-8,18-19,21H2,1H3,(H,39,44)/t28-,30-/m0/s1
Standard InChI Key: CHBPPCMRSQRQHN-JDXGNMNLSA-N
Associated Targets(Human)
DCN1-like protein 1/NEDD8-conjugating enzyme Ubc12 236 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 619.66 | Molecular Weight (Monoisotopic): 619.2570 | AlogP: 6.31 | #Rotatable Bonds: 7 |
| Polar Surface Area: 70.47 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
| #RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 12.33 | CX Basic pKa: 6.83 | CX LogP: 6.00 | CX LogD: 5.90 |
| Aromatic Rings: 4 | Heavy Atoms: 45 | QED Weighted: 0.25 | Np Likeness Score: -1.34 |
References
| 1. Kim HS, Hammill JT, Scott DC, Chen Y, Rice AL, Pistel W, Singh B, Schulman BA, Guy RK.. (2021) Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M., 64 (9.0): [PMID:33945681] [10.1021/acs.jmedchem.1c00035] |
Source
Source(1):